PF-Atlas › Clinical Trials › NCT03286556

Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Autoantibody Reductive Therapy · Phase 2

Registry ID
NCT03286556
Phase
Phase 2
Status
Completed
Drug / intervention
Autoantibody Reductive Therapy
Sponsor
University of Alabama at Birmingham
Start
2018-09-04

About this trial

Autoantibody Reductive Therapy is evaluated in NCT03286556, a Phase 2 idiopathic pulmonary fibrosis study sponsored by University of Alabama at Birmingham. Current status: Completed.

View NCT03286556 on ClinicalTrials.gov →

Explore related

All Autoantibody Reductive Therapy trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03286556 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.